RT Journal
A1 Maxwell W, Bennett CL
T1 Will newer anticoagulants improve therapy persistence?: Comment on “persistence with therapy among patients treated with warfarin for atrial fibrillation”
JF Archives of Internal Medicine
JO Archives of Internal Medicine
YR 2012
FD November 26
VO 172
IS 21
SP 1689
OP 1690
DO 10.1001/2013.jamainternmed.616
UL http://dx.doi.org/10.1001/2013.jamainternmed.616
AB 
A trial fibrillation (AF) continues to be a leading cause of cerebrovascular morbidity and mortality resulting from cardioembolic stroke. When used appropriately, oral anticoagulation therapy has been shown to decrease the incidence of cardioembolic stroke in patients with AF by 50% to 60%.1 Appropriate use of warfarin anticoagulation requires precise adherence and monitoring to optimize the risk to benefit ratio associated with therapy and to ensure that therapy can be safely continued throughout the prescribed duration.